New combo therapy shows promise for Hard-to-Treat cancers
NCT ID NCT01787500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of three drugs—vemurafenib, cetuximab, and irinotecan—in 47 people with advanced solid tumors that have a specific BRAF V600 mutation and could not be removed by surgery or had spread. The main goal was to find the safest dose and understand side effects. The approach aims to block cancer growth and help the immune system attack tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Vaccine trains immune system to hunt down cancer cells
- Gut radiation may revive immunotherapy in resistant cancers
- One shot: could a single radiation dose control metastatic cancer?
- Can talking about stress ease Cancer's mental toll? new study aims to find out
- Mayo clinic hunts for hidden cancer clues in DNA and proteins